FTC Takes Aim At Generics Pay for Delay

A top priority this year at the Federal Trade Commission (FTC) is to stop "pay-for-delay" agreements between branded and generic drug manufacturers, FTC Chairman Jon Leibowitz told the House Judiciary Subcommittee on Courts and Competition Policy Tuesday.

Name:
E-mail:
Website:
Please enter your comment below:

Please enter the text below: